Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to examine the tolerability and antiviral activity of switching to Biktarvy tablets taken once daily compared to baseline over 48 weeks in HIV-1 infected antiretroviral therapy (ART) experienced participants aged 55 years and older who are virologically suppressed on a current antiretroviral regimen (CAR) which includes a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and /or a Protease Inhibitor (PI).

Trial Profile

A pilot study to examine the tolerability and antiviral activity of switching to Biktarvy tablets taken once daily compared to baseline over 48 weeks in HIV-1 infected antiretroviral therapy (ART) experienced participants aged 55 years and older who are virologically suppressed on a current antiretroviral regimen (CAR) which includes a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and /or a Protease Inhibitor (PI).

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2018

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top